PMC9513597_01
Timeline of clinical symptoms with relevant laboratory parameters and treatments.
fimmu-13-930031-g001.jpg
PMC9513597_01_fimmu-13-930031-g001.jpg
f1
At 6 weeks post-gene therapy, he developed rapid neurological deterioration with bilateral squint, inability to fix and follow, upgazing episodes, limb dyskinesia and dystonic movements, truncal hypotonia, and encephalopathy (Figure 1).
Pretreatment MRI-Brain demonstrating T2 hyperintense signal in midbrain (left) and hyperintense Fluid attenuated inversion recovery (FLAIR) signal in both thalami and midbrain (right).
fimmu-13-930031-g002.jpg
PMC9513597_01_fimmu-13-930031-g002.jpg
f2
MRI demonstrated abnormal T2 signal in thalami and brainstem with some restricted diffusion suggestive of viral encephalitis (Figure 2).